Results 61 to 70 of about 2,224,846 (160)

Luteolin enhances erlotinib’s cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines

Frontiers in Pharmacology, 2022
The epidermal growth factor (EGFR) receptor is frequently overexpressed in glioblastoma multiforme IV (GBM). Increased expression of EGFR leads to increased proliferation, decreased apoptosis, and increased resistance to chemotherapeutic agents.
Erika Powe, Daniel Parschauer, Jessica Istifan, Stacy Lin, Huanyun Duan, Rebecca Gryka, Denise Jean-Louis, Amit K. Tiwari, Amit K. Tiwari, Amit K. Tiwari, Samson Amos   +10 more
doaj   +1 more source

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.

PLoS ONE, 2012
Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent against cancer due to its relatively low side-effect profile and, at times, greater efficacy.
Jasmine G Lee, Reen Wu
doaj   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, Volume 159, Issue 10, Page 2575-2584, 15 November 2026.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

Pharmacological modulation and manipulation of cancer drug resistance [PDF]

, 2010
The aim of this project was to investigate pharmacological methods of overcoming resistance in cancer. Novel compounds, targeted therapies and non-steroidal anti-inflammatory drugs (NSAIDs) were examined for their potential to modulate and manipulate ...
Devery, Aoife
core   +2 more sources

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment

BMC Cancer, 2018
Background Lung cancer patients with an activating mutation in the EGFR (epidermal growth factor receptor) can develop resistance to erlotinib treatment, which is often mediated by the T790M resistance mutation in EGFR.
Christina Demuth, Anne Tranberg Madsen, Britta Weber, Lin Wu, Peter Meldgaard, Boe Sandahl Sorensen   +5 more
doaj   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan, Mariah Wright‐Nadkarni, Mohamed S. Abdelbaki, Girish Dhall   +3 more
wiley   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

International Journal of Cancer, Volume 159, Issue 9, Page 2244-2261, 1 November 2026.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, Mikhail Fedyanin, Albina Gabina, Ani Oganesian, Sergey Belukhin, Maria Stepanova, Ekaterina Stepanova, Elizaveta Artemyeva, Alexander Myslik, Nikita Volkov, Alexei Bogdanov, Tatiana Shuginova, Kirill Kryukov, Valeria Kheinshtein, Arif Allakhverdiev, Ivan Zaberegniy, Yana Akhmadiyarova, Mikhail Popov, Anastasiya Danilova, Dmitriy Sehniaidze, Nikita Savelov, Nikita Levchenko, Evgeniy Slugin, Olga Lopushanskaya, Ekaterina Kuligina, Svetlana Aleksakhina, Aglaya Iyevleva, Alexandr Ivantsov, Vladimir Moiseyenko, Evgeny Imyanitov   +31 more
wiley   +1 more source

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Journal for ImmunoTherapy of Cancer, 2019
Background Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges.
Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, Ping-Chih Ho, Camila Robles-Oteiza, Mmaserame Gaefele, Stellar Levy, Fernando J. de Miguel, Curtis Perry, Tianxia Guan, Gerald Krystal, William Lockwood, Daniel Zelterman, Robert Homer, Zongzhi Liu, Susan Kaech, Katerina Politi   +16 more
doaj   +1 more source

Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations

Biomolecular Concepts, 2021
Nowadays, mutations in the epidermal growth factor receptor (EGFR) kinase domain are studied in targeted therapy of non-small cell lung cancer (NSCLC) with EGFR tyrosine kinase inhibitors including gefitinib and erlotinib.
Mirtavoos-mahyari Hanifeh, Rismani Elham, Lotfabadi Alireza Sarkar, Dezfouli Azizollah Abbasi, Sheikhy Kambiz, Dezfuli Mojtaba Mokhber, Heshmatnia Jalal   +6 more
doaj   +1 more source